Agilent Technologies (NYSE:A) Given New $130.00 Price Target at Evercore ISI

Agilent Technologies (NYSE:A) had its price objective hoisted by equities researchers at Evercore ISI from $126.00 to $130.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has an “in-line” rating on the medical research company’s stock. Evercore ISI’s price target would suggest a potential upside of 1.90% from the stock’s current price.

Several other equities analysts also recently commented on A. Bank of America upped their target price on Agilent Technologies from $134.00 to $140.00 and gave the company a “neutral” rating in a research report on Tuesday, June 25th. UBS Group dropped their price target on Agilent Technologies from $155.00 to $141.00 and set a “neutral” rating for the company in a research note on Thursday, May 30th. Stifel Nicolaus dropped their price target on Agilent Technologies from $163.00 to $151.00 and set a “buy” rating for the company in a research note on Thursday, May 30th. Oppenheimer raised their target price on Agilent Technologies from $67.00 to $90.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 26th. Finally, Robert W. Baird lowered their target price on Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating for the company in a research report on Thursday, May 30th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, Agilent Technologies has a consensus rating of “Hold” and an average price target of $137.13.

Agilent Technologies Stock Performance

NYSE:A traded up $0.18 on Tuesday, hitting $127.58. The company’s stock had a trading volume of 217,461 shares, compared to its average volume of 1,781,996. The company has a current ratio of 2.15, a quick ratio of 1.64 and a debt-to-equity ratio of 0.34. The stock has a fifty day moving average of $139.56 and a two-hundred day moving average of $138.50. The firm has a market capitalization of $37.22 billion, a P/E ratio of 30.16, a price-to-earnings-growth ratio of 4.40 and a beta of 1.05. Agilent Technologies has a one year low of $96.80 and a one year high of $155.35.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, May 29th. The medical research company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.03. Agilent Technologies had a return on equity of 26.25% and a net margin of 18.84%. The firm had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.58 billion. During the same quarter in the prior year, the company earned $1.27 earnings per share. The business’s revenue for the quarter was down 8.4% compared to the same quarter last year. Research analysts predict that Agilent Technologies will post 5.25 earnings per share for the current year.

Insider Buying and Selling at Agilent Technologies

In other Agilent Technologies news, SVP Dominique Grau sold 15,000 shares of Agilent Technologies stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the transaction, the senior vice president now owns 49,486 shares of the company’s stock, valued at approximately $6,595,494.08. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $130.00, for a total transaction of $254,540.00. Following the transaction, the chief executive officer now owns 25,185 shares of the company’s stock, valued at approximately $3,274,050. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Dominique Grau sold 15,000 shares of Agilent Technologies stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the transaction, the senior vice president now directly owns 49,486 shares in the company, valued at approximately $6,595,494.08. The disclosure for this sale can be found here.

Institutional Investors Weigh In On Agilent Technologies

Hedge funds have recently modified their holdings of the stock. Livelsberger Financial Advisory bought a new stake in shares of Agilent Technologies in the 4th quarter worth approximately $26,000. MV Capital Management Inc. raised its holdings in Agilent Technologies by 120.7% during the 4th quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 105 shares during the period. VisionPoint Advisory Group LLC bought a new stake in Agilent Technologies during the 4th quarter valued at $29,000. Rise Advisors LLC raised its holdings in Agilent Technologies by 527.8% during the 1st quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 190 shares during the period. Finally, YHB Investment Advisors Inc. bought a new stake in Agilent Technologies during the 1st quarter valued at $34,000.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.